**Question:** A patient of borderline tuberculoid leprosy on treatment develops reaction. What will be the best next line of management -

A. Increase the dose of anti-TB drugs
B. Change the anti-TB drug regime
C. Increase the dose of corticosteroids
D. Start immunomodulatory drugs like thalidomide

**Correct Answer:** D. Start immunomodulatory drugs like thalidomide

**Core Concept:** In leprosy, reactions (also called Type 1 or Reversal Reactions) are immune-mediated responses that can occur during treatment. They are classified into two types:

1. Erythema Nodosum Leproticum (ENL) - a severe, potentially life-threatening reaction characterized by fever, lymphadenopathy, joint pain, and swelling.
2. Type 1 Reversal Reaction - a milder reaction characterized by skin lesions, nerve thickening, and reversal of leprosy reactions.

**Why the Correct Answer is Right:** When a patient with borderline tuberculoid leprosy develops a reaction, the immune system is mounting a robust response against Mycobacterium leprae, the causative agent of leprosy. In borderline tuberculoid leprosy, the initial immune response is Th1-dominated, which leads to the control of the infection. However, during a reaction, the immune response shifts towards a Th2 response, causing inflammation and tissue damage.

**Why Each Wrong Option is Incorrect:**

A. Increasing the dose of anti-TB drugs doesn't address the underlying immune imbalance causing the reaction. Instead, it may exacerbate the reaction due to increased immune response.

B. Changing the anti-TB drug regime is unnecessary unless there is suspected drug resistance or toxicity. A change in the drug regimen is not tailored to the specific immune response during a reaction.

C. Corticosteroids (corticosteroids) are immunosuppressive drugs that can dampen the immune response, which is crucial for the control of M. leprae infection in leprosy. Using corticosteroids might lead to reactivation of the infection and worsen the patient's condition.

D. Immunomodulatory drugs like thalidomide (e.g., thalidomide) can help modulate the immune response during a reaction. Thalidomide modulates the immune response, reducing inflammation and tissue damage caused by the shift towards a Th2 response during a reaction. This is the correct choice for managing reactions in leprosy patients.

**Clinical Pearl:** In borderline tuberculoid leprosy, reactions (Type 1 reactions or ENL) can be severe and potentially life-threatening. A Type 1 reaction is managed with thalidomide or its derivatives, as they help to modulate the immune response and reduce inflammation and tissue damage. In contrast, corticosteroids should be avoided, as they suppress the immune response, leading to reactivation of the infection and worsening of the patient's condition.